Relieva
Relieva is redefining therapeutic innovation through the world’s first proprietary cannabis and hemp pre-roll blend engineered for targeted pain relief. Leveraging advanced cannabinoid and terpene research, Relieva integrates scientific precision, sustainable production, and blockchain-enabled IP tokenization to establish a new benchmark in functional medicine innovation and therapeutic transparency.
Community Sentiment
How do you feel about this ipt?
Community Sentiment
How do you feel about this ipt?
Loading chart data...
Loading trading interface...
Project
Market Overview
Summary
Relieva is a proprietary cannabis and hemp-derived pre-roll blend formulated for pain relief. Using New Leaf’s unique strain portfolio, it standardizes cannabinoid and terpene compositions to deliver consistent, therapeutic formulations for targeted wellness applications.
Problem
Current cannabis products lack standardized, scientifically validated formulations for pain relief. Consumers face inconsistent effects and limited access to compliant, data-driven solutions that bridge the gap between medical efficacy and wellness-oriented use.
Impact
Relieva pioneers functional, compliant cannabis formulations that combine plant science and technology to deliver consistent pain relief. By leveraging automated production and proprietary blends, it positions itself to lead the $125B global wellness cannabis market.
Market Overview
Summary
Relieva is a proprietary cannabis and hemp-derived pre-roll blend formulated for pain relief. Using New Leaf’s unique strain portfolio, it standardizes cannabinoid and terpene compositions to deliver consistent, therapeutic formulations for targeted wellness applications.
Problem
Current cannabis products lack standardized, scientifically validated formulations for pain relief. Consumers face inconsistent effects and limited access to compliant, data-driven solutions that bridge the gap between medical efficacy and wellness-oriented use.
Impact
Relieva pioneers functional, compliant cannabis formulations that combine plant science and technology to deliver consistent pain relief. By leveraging automated production and proprietary blends, it positions itself to lead the $125B global wellness cannabis market.
The project captures value by issuing tokens that grant holders fractional rights to revenue generated from intellectual property licensing. These tokens entitle users to a share of royalty streams, aligning incentives between IP creators and token holders.
Additionally, token ownership provides privileged access to data rooms, research and development updates, and opportunities for exclusive licensing. This model not only monetizes IP assets but also fosters a community of engaged stakeholders who benefit directly from the project’s commercial success.
Phase I — Research & Formulation
Identify target outcomes and map active compound combinations
Phase II — Pilot Manufacturing
Produce small batches for lab and sensory testing under regulatory standards
Phase III — IP Protection
File patents and trademarks for novel formulations, processes, and branding
Phase IV — Brand & Regulatory Positioning
Establish compliant wellness product positioning with FDA and other regulators
Phase V — Market Testing
Soft launch via pilot retail or e-commerce channels to gather consumer insights and early revenues
Medicinal Properties of Cannabinoids, Terpenes, and Flavonoids in Cannabis, and Benefits in Migraine, Headache, and Pain: An Update on Current Evidence and Cannabis Science
https://headachejournal.onlinelibrary.wiley.com/doi/10.1111/head.13345
The holistic effects of medical cannabis compared to opioids on pain experience in Finnish patients with chronic pain
https://jcannabisresearch.biomedcentral.com/articles/10.1186/s42238-023-00207-7
Efficacy of Cannabis-Based Medicines for Pain Management: A Systematic Review and Meta-Analysis of Randomized Controlled Trials
https://www.painphysicianjournal.com/linkout?issn=&vol=20&page=E755
Antinociceptive effects of minor cannabinoids, terpenes and flavonoids in Cannabis
https://journals.lww.com/behaviouralpharm/abstract/2022/04000/antinociceptive_effects_of_minor_cannabinoids,.5.aspx
Tokenomics
10,000,000
Total SupplyIgnition Sale | 10% |
Wide Liquidity | 22.5% |
Concentrated Liquidity | 15% |
Team | 10% |
Treasury | 35% |
Bio Protocol Call Option | 2.5% |
veBIO Airdrop | 5% |
10,000,000
Total SupplyIgnition Sale | 10% |
Wide Liquidity | 22.5% |
Concentrated Liquidity | 15% |
Team | 10% |
Treasury | 35% |
Bio Protocol Call Option | 2.5% |
veBIO Airdrop | 5% |
Community
Stay up to date
Get the latest community updates and find out about upcoming Relieva developments
